Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Inception Modules Enhance Brain Tumor Segmentation.

Cahall DE, Rasool G, Bouaynaya NC, Fathallah-Shaykh HM.

Front Comput Neurosci. 2019 Jul 12;13:44. doi: 10.3389/fncom.2019.00044. eCollection 2019.

2.

Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study.

Fathallah-Shaykh HM, DeAtkine A, Coffee E, Khayat E, Bag AK, Han X, Warren PP, Bredel M, Fiveash J, Markert J, Bouaynaya N, Nabors LB.

PLoS Med. 2019 May 28;16(5):e1002810. doi: 10.1371/journal.pmed.1002810. eCollection 2019 May.

3.

Approximate kernel reconstruction for time-varying networks.

Ditzler G, Bouaynaya N, Shterenberg R, Fathallah-Shaykh HM.

BioData Min. 2019 Feb 6;12:5. doi: 10.1186/s13040-019-0192-1. eCollection 2019.

4.

Key rates for the grades and transformation ability of glioma: model simulations and clinical cases.

Scribner E, Hackney JR, Machemehl HC, Afiouni R, Patel KR, Fathallah-Shaykh HM.

J Neurooncol. 2017 Jun;133(2):377-388. doi: 10.1007/s11060-017-2444-6. Epub 2017 Apr 27.

PMID:
28451993
5.

Single Cell Mathematical Model Successfully Replicates Key Features of GBM: Go-Or-Grow Is Not Necessary.

Scribner E, Fathallah-Shaykh HM.

PLoS One. 2017 Jan 3;12(1):e0169434. doi: 10.1371/journal.pone.0169434. eCollection 2017.

6.

Automated Robust Image Segmentation: Level Set Method Using Nonnegative Matrix Factorization with Application to Brain MRI.

Dera D, Bouaynaya N, Fathallah-Shaykh HM.

Bull Math Biol. 2016 Jul;78(7):1450-76. doi: 10.1007/s11538-016-0190-0. Epub 2016 Jul 14.

PMID:
27417984
7.

Computational Trials: Unraveling Motility Phenotypes, Progression Patterns, and Treatment Options for Glioblastoma Multiforme.

Raman F, Scribner E, Saut O, Wenger C, Colin T, Fathallah-Shaykh HM.

PLoS One. 2016 Jan 12;11(1):e0146617. doi: 10.1371/journal.pone.0146617. eCollection 2016.

8.

Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.

Wen PY, Omuro A, Ahluwalia MS, Fathallah-Shaykh HM, Mohile N, Lager JJ, Laird AD, Tang J, Jiang J, Egile C, Cloughesy TF.

Neuro Oncol. 2015 Sep;17(9):1275-83. doi: 10.1093/neuonc/nov083. Epub 2015 May 26.

9.

Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas.

Bag AK, Kim H, Gao Y, Bolding M, Warren PP, Fathallah-Shaykh HM, Gurler D, Markert JM, Fiveash J, Beasley TM, Khawaja A, Friedman GK, Chapman PR, Nabors LB, Han X.

J Neurooncol. 2015 May;122(3):585-93. doi: 10.1007/s11060-015-1751-z. Epub 2015 Feb 25.

PMID:
25711673
10.

Effects of anti-angiogenesis on glioblastoma growth and migration: model to clinical predictions.

Scribner E, Saut O, Province P, Bag A, Colin T, Fathallah-Shaykh HM.

PLoS One. 2014 Dec 15;9(12):e115018. doi: 10.1371/journal.pone.0115018. eCollection 2014.

11.

Case 212: chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids.

Bag AK, Davenport JJ, Hackney JR, Roy R, Fathallah-Shaykh HM.

Radiology. 2014 Dec;273(3):940-7. doi: 10.1148/radiol.14131355.

PMID:
25420171
12.

A multilayer grow-or-go model for GBM: effects of invasive cells and anti-angiogenesis on growth.

Saut O, Lagaert JB, Colin T, Fathallah-Shaykh HM.

Bull Math Biol. 2014 Sep;76(9):2306-33. doi: 10.1007/s11538-014-0007-y. Epub 2014 Aug 23.

PMID:
25149139
13.

Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.

Bag AK, Cezayirli PC, Davenport JJ, Gaddikeri S, Fathallah-Shaykh HM, Cantor A, Han XS, Nabors LB.

J Neurooncol. 2014 Nov;120(2):361-70. doi: 10.1007/s11060-014-1560-9. Epub 2014 Aug 7.

14.

The role of Src family kinases in growth and migration of glioma stem cells.

Han X, Zhang W, Yang X, Wheeler CG, Langford CP, Wu L, Filippova N, Friedman GK, Ding Q, Fathallah-Shaykh HM, Gillespie GY, Nabors LB.

Int J Oncol. 2014 Jul;45(1):302-10. doi: 10.3892/ijo.2014.2432. Epub 2014 May 9.

15.

Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.

Han X, Li R, Zhang W, Yang X, Wheeler CG, Friedman GK, Province P, Ding Q, You Z, Fathallah-Shaykh HM, Gillespie GY, Zhao X, King PH, Nabors LB.

J Neurooncol. 2014 May;118(1):61-72. doi: 10.1007/s11060-014-1419-0. Epub 2014 Mar 25.

16.

Tracking of time-varying genomic regulatory networks with a LASSO-Kalman smoother.

Khan J, Bouaynaya N, Fathallah-Shaykh HM.

EURASIP J Bioinform Syst Biol. 2014 Feb 12;2014(1):3. doi: 10.1186/1687-4153-2014-3.

17.

c-Src and neural Wiskott-Aldrich syndrome protein (N-WASP) promote low oxygen-induced accelerated brain invasion by gliomas.

Tang Z, Araysi LM, Fathallah-Shaykh HM.

PLoS One. 2013 Sep 19;8(9):e75436. doi: 10.1371/journal.pone.0075436. eCollection 2013.

18.

Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme.

Griguer CE, Cantor AB, Fathallah-Shaykh HM, Gillespie GY, Gordon AS, Markert JM, Radovanovic I, Clement-Schatlo V, Shannon CN, Oliva CR.

PLoS One. 2013 Apr 10;8(4):e61035. doi: 10.1371/journal.pone.0061035. Print 2013.

19.

Primary central nervous system angiosarcoma: two case reports.

Hackney JR, Palmer CA, Riley KO, Cure JK, Fathallah-Shaykh HM, Nabors LB.

J Med Case Rep. 2012 Aug 21;6:251.

20.

Pontine ring-enhancing glioblastoma multiforme-like fungal abscess.

Province P, Hackney JR, Palmer CA, Guthrie BL, Fathallah-Shaykh HM.

Arch Neurol. 2011 Nov;68(11):1476-7. doi: 10.1001/archneurol.2011.755. No abstract available.

PMID:
22084135
21.

Gene expression analysis in radiotherapy patients and C57BL/6 mice as a measure of exposure to ionizing radiation.

Filiano AN, Fathallah-Shaykh HM, Fiveash J, Gage J, Cantor A, Kharbanda S, Johnson MR.

Radiat Res. 2011 Jul;176(1):49-61. doi: 10.1667/RR2419.1. Epub 2011 Mar 1.

PMID:
21361780
22.

Modeling of regulatory networks: theory and applications in the study of the Drosophila circadian clock.

Scribner EY, Fathallah-Shaykh HM.

Methods Enzymol. 2011;487:39-71. doi: 10.1016/B978-0-12-381270-4.00002-0.

PMID:
21187221
23.

Dynamics of the Drosophila circadian clock: theoretical anti-jitter network and controlled chaos.

Fathallah-Shaykh HM.

PLoS One. 2010 Oct 13;5(10):e11207. doi: 10.1371/journal.pone.0011207.

24.

Apparent widening gap in access to neuro-oncologic care in the United States: need for action.

Riley K, Fathallah-Shaykh HM.

Arch Neurol. 2010 Sep;67(9):1137-9. doi: 10.1001/archneurol.2010.217. No abstract available.

PMID:
20837860
25.

Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome.

Grunda JM, Fiveash J, Palmer CA, Cantor A, Fathallah-Shaykh HM, Nabors LB, Johnson MR.

Clin Cancer Res. 2010 May 15;16(10):2890-8. doi: 10.1158/1078-0432.CCR-09-3151. Epub 2010 May 11.

26.

Bevacizumab is active as a single agent against recurrent malignant gliomas.

Agha CA, Ibrahim S, Hassan A, Elias DA, Fathallah-Shaykh HM.

Anticancer Res. 2010 Feb;30(2):609-11.

PMID:
20332478
27.

Malignant astrocytomas: a system disease.

Fathallah-Shaykh HM.

Arch Neurol. 2010 Mar;67(3):353-5. doi: 10.1001/archneurol.2010.19. No abstract available.

PMID:
20212234
28.

A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.

Nabors LB, Fiveash JB, Markert JM, Kekan MS, Gillespie GY, Huang Z, Johnson MJ, Meleth S, Kuo H, Gladson CL, Fathallah-Shaykh HM.

Arch Neurol. 2010 Mar;67(3):313-9. doi: 10.1001/archneurol.2010.16.

29.

Optic neuropathy in patients with glioblastoma receiving bevacizumab.

Sherman JH, Aregawi DG, Lai A, Fathallah-Shaykh HM, Bierman PJ, Linsky K, Larner JM, Newman SA, Schiff D.

Neurology. 2009 Dec 1;73(22):1924-6. doi: 10.1212/WNL.0b013e3181c3fd00. No abstract available.

30.

Mathematical model of the Drosophila circadian clock: loop regulation and transcriptional integration.

Fathallah-Shaykh HM, Bona JL, Kadener S.

Biophys J. 2009 Nov 4;97(9):2399-408. doi: 10.1016/j.bpj.2009.08.018.

31.

Microarrays: applications and pitfalls.

Fathallah-Shaykh HM.

Arch Neurol. 2005 Nov;62(11):1669-72. Review.

PMID:
16286538
32.

Noise and rank-dependent geometrical filter improves sensitivity of highly specific discovery by microarrays.

Fathallah-Shaykh HM.

Bioinformatics. 2005 Dec 1;21(23):4255-62. Epub 2005 Sep 22.

PMID:
16179359
33.
35.

Mathematical algorithm for discovering states of expression from direct genetic comparison by microarrays.

Fathallah-Shaykh HM, He B, Zhao LJ, Badruddin A.

Nucleic Acids Res. 2004 Jul 20;32(13):3807-14. Print 2004.

36.

Genomic expression discovery predicts pathways and opposing functions behind phenotypes.

Fathallah-Shaykh HM, He B, Zhao LJ, Engelhard HH, Cerullo L, Lichtor T, Byrne R, Munoz L, Von Roenn K, Rosseau GL, Glick R, Sherman C, Farooq K.

J Biol Chem. 2003 Jun 27;278(26):23830-3. Epub 2003 Apr 16.

37.

Mathematical modeling of noise and discovery of genetic expression classes in gliomas.

Fathallah-Shaykh HM, Rigen M, Zhao LJ, Bansal K, He B, Engelhard HH, Cerullo L, Roenn KV, Byrne R, Munoz L, Rosseau GL, Glick R, Lichtor T, DiSavino E.

Oncogene. 2002 Oct 17;21(47):7164-74.

38.

Darts in the dark cure animal, but not human, brain tumors.

Fathallah-Shaykh HM.

Arch Neurol. 2002 May;59(5):721-4. Review. No abstract available.

PMID:
12020251
39.

Survival in a transgenic model of FALS is independent of iNOS expression.

Son M, Fathallah-Shaykh HM, Elliott JL.

Ann Neurol. 2001 Aug;50(2):273. No abstract available.

PMID:
11506415
40.

Demyelination but no cognitive, motor or behavioral deficits after adenovirus-mediated gene transfer into the brain.

Fathallah-Shaykh HM, Kafrouni AI, Zhao LJ, Diaz-Arrastia R, Garcia JA, Frawley WH, Forman J.

Gene Ther. 2000 Dec;7(24):2094-8.

41.

Molecular advances to treat cancer of the brain.

Fathallah-Shaykh HM, Zhao LJ, Mickey B, Kafrouni AI.

Expert Opin Investig Drugs. 2000 Jun;9(6):1207-15. Review.

PMID:
11060737
42.

Gene transfer into brain parenchyma elicits antitumor effects.

Fathallah-Shaykh HM, Kafrouni AI, Zhao LJ, Smith GM, Forman J.

Cancer Res. 2000 Apr 1;60(7):1797-9.

43.

Fiction, reality, and molecular neurology.

Fathallah-Shaykh HM.

Arch Neurol. 2000 Jan;57(1):63-4. No abstract available.

PMID:
10634449
44.

Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis.

Fathallah-Shaykh HM, Zhao LJ, Kafrouni AI, Smith GM, Forman J.

J Immunol. 2000 Jan 1;164(1):217-22.

45.

Paraneoplastic neurological syndromes: paraneoplastic or neurological?

Fathallah-Shaykh HM.

Arch Neurol. 1999 Feb;56(2):151-2. No abstract available.

PMID:
10025419
46.

Brain tumors in the elderly: undefeated and gaining ground.

Fathallah-Shaykh HM, McIntire DD.

Arch Neurol. 1998 Jul;55(7):905-6. No abstract available.

PMID:
9678306
47.

Priming in the brain, an immunologically privileged organ, elicits anti-tumor immunity.

Fathallah-Shaykh HM, Gao W, Cho M, Herrera MA.

Int J Cancer. 1998 Jan 19;75(2):266-76.

48.

Response of primary leptomeningeal melanoma to intrathecal recombinant interleukin-2. A case report.

Fathallah-Shaykh HM, Zimmerman C, Morgan H, Rushing E, Schold SC Jr, Unwin DH.

Cancer. 1996 Apr 15;77(8):1544-50.

PMID:
8608541

Supplemental Content

Loading ...
Support Center